Propanc Biopharma Announces Publication of Pilot Study Demonstrating Potent Anti-Tumor Efficacy of PRP Pancreatic Proenzyme Formulation in Pancreatic & Ovarian Cancer

Go back to Propanc Biopharma Announces Publication of Pilot Study Demonstrating Potent Anti-Tumor Efficacy of PRP Pancreatic Proenzyme Formulation in Pancreatic & Ovarian Cancer
(NASDAQ: PPCB) Delayed: 0.28 +0.01 (3.70%)
Previous Close $0.27    52 Week High $ 
Open $0.28    52 Week Low $ 
Day High $0.28    P/E N/A 
Day Low $0.25    EPS $ 
Volume 252,724